Perioperative von Willebrand factor dynamics are associated with liver regeneration and predict outcome after liver resection

Patrick Starlinger, David Pereyra, Stefanie Haegele, Paul Braeuer, Lukas Oehlberger, Florian Primavesi, Andreas Kohler, Florian Offensperger, Thomas Reiberger, Arnulf Ferlitsch, Barbara Messner, Guido Beldi, Stefan Staettner, Christine Brostjan, Thomas Gruenberger – 15 November 2017 – von Willebrand Factor (vWF) was found to mediate platelet influx during the early phase of liver regeneration in mice. Furthermore, increased vWF‐antigen (vWF‐Ag) levels were shown to be predictive for outcome of patients with chronic liver disease.

Long noncoding RNA H19 interacts with polypyrimidine tract‐binding protein 1 to reprogram hepatic lipid homeostasis

Chune Liu, Zhihong Yang, Jianguo Wu, Li Zhang, Sangmin Lee, Dong‐Ju Shin, Melanie Tran, Li Wang – 15 November 2017 – H19 is an imprinted long noncoding RNA abundantly expressed in embryonic liver and repressed after birth. We show that H19 serves as a lipid sensor by synergizing with the RNA‐binding polypyrimidine tract‐binding protein 1 (PTBP1) to modulate hepatic metabolic homeostasis. H19 RNA interacts with PTBP1 to facilitate its association with sterol regulatory element‐binding protein 1c mRNA and protein, leading to increased stability and nuclear transcriptional activity.

β‐Catenin and interleukin‐1β–dependent chemokine (C‐X‐C motif) ligand 10 production drives progression of disease in a mouse model of congenital hepatic fibrosis

Eleanna Kaffe, Romina Fiorotto, Francesca Pellegrino, Valeria Mariotti, Mariangela Amenduni, Massimiliano Cadamuro, Luca Fabris, Mario Strazzabosco, Carlo Spirli – 15 November 2017 – Congenital hepatic fibrosis (CHF), a genetic disease caused by mutations in the polycystic kidney and hepatic disease 1 (PKHD1) gene, encoding for the protein fibrocystin/polyductin complex, is characterized by biliary dysgenesis, progressive portal fibrosis, and a protein kinase A–mediated activating phosphorylation of β‐catenin at Ser675.

Newly discovered hepatitis C virus minicores circulate in human blood

Francis J. Eng, Ahmed El‐Shamy, Erin H. Doyle, Arielle Klepper, A. Scott Muerhoff, Andrea D. Branch – 12 November 2017 – Hepatitis C virus (HCV) is one of the most prevalent causes of chronic blood‐borne infections worldwide. Despite developments of highly effective treatments, most infected individuals are unaware of their infection. Approximately 75% of infections are in low‐ and middle‐income countries; therefore, continuing research in HCV molecular virology and the development of vaccines and affordable diagnostics is required to reduce the global burden.

Osteopontin deletion drives hematopoietic stem cell mobilization to the liver and increases hepatic iron contributing to alcoholic liver disease

Fernando Magdaleno, Xiaodong Ge, Holger Fey, Yongke Lu, Harriet Gaskell, Chuck C. Blajszczak, Costica Aloman, M. Isabel Fiel, Natalia Nieto – 12 November 2017 – The aim of this study was to investigate the role of osteopontin (OPN) in hematopoietic stem cell (HPSC) mobilization to the liver and its contribution to alcoholic liver disease (ALD). We analyzed young (14‐16 weeks) and old (>1.5 years) wild‐type (WT) littermates and global Opn knockout (Opn−/−) mice for HPSC mobilization to the liver. In addition, WT and Opn−/− mice were chronically fed the Lieber–DeCarli diet for 7 weeks.

Sex‐specific analysis post‐liver transplantation in hemochromatosis with aplastic anemia and hepatocellular carcinoma

Paul Adams, Christopher Howlett, Anargyros Xenocostas, Subrata Chakrabarti – 11 November 2017 – A 42‐year‐old man with hemochromatosis and cirrhosis developed aplastic anemia. He underwent liver transplantation from a female donor and splenectomy, and his aplastic anemia spontaneously resolved. A bone marrow examination 6 months after the liver transplant showed 17.5% female cells. He did well for 13 years without the need for any blood product support but then developed bone pain and was found to have metastatic hepatocellular carcinoma in the vertebral bodies.

Sofosbuvir induced steven Johnson Syndrome in a patient with hepatitis C virus‐related cirrhosis

Nipun Verma, Shreya Singh, Gitesh Sawatkar, Virendra Singh – 11 November 2017 – Sofosbuvir is an imperative drug used in treatment regimens for hepatitis C virus (HCV). It is considered relatively safe with fewer adverse effects than other treatments. Here, we report a rare and potentially serious, dermatologic, adverse effect following the use of sofosbuvir. A 35‐year‐old man with genotype 3‐related HCV cirrhosis presented with decompensated ascites and jaundice following 7 weeks of therapy with peginterferon alpha‐2a and oral ribavirin.

Subscribe to